Hep C - Valeant buys InterMune hepatitis C drug

Valeant buys InterMune hepatitis C drug
San Francisco Business Journal - Valeant Pharmaceuticals International said Tuesday it closed its purchase of the United States and Canadian rights to hepatitis C drug Infergen from InterMune Inc. for $113.5 million in cash. Brisbane-based InterMune (NASDAQ: ITMN) also will receive

Idenix and Novartis announce new drug application submitted to the U.S
WebWire - East Hanover, NJ, January 3, 2006 - Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX) and Novartis Pharmaceuticals Corporation (NYSE: NVS) announced today that a New Drug Application (NDA) was submitted to the United States Food and Drug Administration

Biochemical connection between hepatitis C virus and liver cancer
Xagena Medical News - Researchers at the University of Texas Medical Branch at Galveston ( UTMB ) have identified a key biochemical connection between the hepatitis C virus and liver cancer. According to Stanley M. Lemon, the senior author of a paper, the molecular

Diazyme Receives FDA 510(K) Approval for Enzymatic Total Bile Acids
Market Wire - SAN DIEGO, CA -- (MARKET WIRE) -- 12/22/2005 -- Diazyme Laboratories, a company that applies its proprietary enzyme technologies to develop low cost and high quality diagnostic products for clinical and research uses, announced today that the U.S

Interferon with Ribavirin is safe and effective for children with
Xagena Medical News - Nearly half of 118 children with chronic Hepatitis C virus ( HCV ) treated with a combination of Interferon-alpha-2b ( Intron A ) and an optimized dose of Ribavirin ( Rebetol ) achieved sustained viral response, and side effects were generally mild